zepbound eli lilly - Search News

News

Texas AG sues Eli Lilly over alleged kickbacks

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Texas Sues Eli Lilly: 'Big Pharma Compromised Medical Decision-Making'

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its most profitable drugs, including the high-demand GLP-1 medications Mounjaro and Zepbound that are used for weight loss and diabetes treatment.

Houston Chronicle · 3d

Texas sues, accusing Eli Lilly of 'bribing' physicians to prescribe Zepbound, Mounjaro and other drugs

Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as administrative support services that helped providers process insurance claims.

Eli Lilly raises price of diabetes drug Mounjaro

Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss. Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027.

CNBC on MSN · 1d

Eli Lilly raises price of diabetes drug Mounjaro in UK ahead of Trump deadline

Dr. Kavita Patel, NBC News & MSNBC medical contributor, joins 'Fast Money' to talk Eli Lilly raising Mounjaro prices.

Barron's on MSN · 1d

Eli Lilly Says It Will Raise European Prices of its Medicines as Trump Pushes for U.S. Price Cuts

The White House’s effort to lower drug prices in the U.S. is bringing higher drug prices to Europe. The Indiana-based drugmaker Eli Lilly said on Thursday that it is raising the list prices of its drugs overseas.

9don MSN

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

1d

Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

1don MSN

Novo Nordisk Stock Could Benefit From Eli Lilly’s Weight-Loss Price Hikes

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

9d

Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

8don MSN

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Zacks.com on MSN5d

Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

5don MSN

Leerink Downgrades Eli Lilly and Company (LLY) to Market Perform From Outperform

Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results